Prospective Epidemiological Study of Metastatic Non Small Cell Lung Cancer (NSCLC) in Latin America
LATINO Lung
1 other identifier
observational
700
5 countries
27
Brief Summary
To describe the overall survival of advanced NSCLC in Latin America.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jul 2018
Longer than P75 for all trials
27 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 11, 2018
CompletedStudy Start
First participant enrolled
July 25, 2018
CompletedFirst Posted
Study publicly available on registry
January 13, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 4, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
August 4, 2023
CompletedFebruary 20, 2024
February 1, 2024
3.2 years
January 11, 2018
February 18, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Overall survival of advanced NSCLC in Latin America
Time from randomization or initiation of treatment to patient death
Annually, during 3 years
Secondary Outcomes (5)
Description of socioeconomic characteristics of patients newly diagnosed with advanced NSCLC
Annually, during 3 years
Description of pathological profile of advanced NSCLC
Annually, during 3 years
Description of the practice patterns of therapeutic agents for treatment of advanced NSCLC
Annually, during 3 years
Description of the treatment responses
Annually, during 3 years
Description of Treatment discontinuation
Annually, during 3 years
Eligibility Criteria
The LATINO Lung study will prospectively recruit a minimum of 700 and up to 800 patients with advanced NSCLC, including locally advanced disease not amenable to curative treatment or metastatic disease from sites in Argentina, Brazil, Chile, Colombia, and Mexico. Other countries may be invited to participate. Patients will be recruited during an initial study period of 3 months, or more to reach the study minimum sample size, and will be followed for 3 years.
You may qualify if:
- Patients aged 18 years or older;
- Newly diagnosed Non-Small Cell Lung Cancer (NSCLC) during the period of the study (which includes 3 months prior to site activation by LACOG, although they can have received anti-cancer treatment during that time);
- Histologically or cytologically confirmed advanced NSCLC:
- Stage IIIB that progressed after curative therapy (chemoradiation and/or surgery);
- Stage IV metastatic disease (de novo or distant relapse)
- Any NSCLC histological subtype and molecular mutation;
- Any Eastern Cooperative Oncology Group (ECOG) Performance Status (0 to 4) at diagnosis;
- Patients assigned by treating physician to any therapy (i.e. chemotherapy, targeted agents, immunotherapy) or palliative care;
- Access to patient medical chart for data collection;
- Willing and able to provide written informed consent and privacy authorization for the release of personal health information.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Latin American Cooperative Oncology Grouplead
- Bristol-Myers Squibbcollaborator
Study Sites (27)
Centro Oncologico Riojano
La Rioja, Rioja, Argentina
Instituto De Oncologia De Rosario
Santa Fe, Rosário, Argentina
Centro Medico San Roque
Córdoba, Tucumán Province, Argentina
CRIO
Fortaleza, Ceará, Brazil
CLION
Salvador, Estado de Bahia, Brazil
NOB
Salvador, Estado de Bahia, Brazil
Hospital Sírio- Libanês
Brasília, Federal District, Brazil
ICTr
Curitiba, Paraná, Brazil
Hospital de Câncer de Londrina
Londrina, Paraná, Brazil
Hospital de Caridade de Carazinho
Carazinho, Rio Grande do Sul, Brazil
CPO
Porto Alegre, Rio Grande do Sul, Brazil
HCPA
Porto Alegre, Rio Grande do Sul, Brazil
Hospital Moinhos de Vento
Porto Alegre, Rio Grande do Sul, Brazil
Hospital Mãe de Deus
Porto Alegre, Rio Grande do Sul, Brazil
Clínica Reichow
Blumenau, Santa Catarina, Brazil
CNT Itajaí
Itajaí, Santa Catarina, Brazil
Barretos
Barretos, São Paulo, Brazil
COI Américas
Rio de Janeiro, Brazil
INCA
Rio de Janeiro, Brazil
AC Camargo
São Paulo, Brazil
IBCC
São Paulo, Brazil
Fundación Arturo López Pérez
Providencia, Santiago Metropolitan, Chile
Clínica del Country
Chapinero, Bogota D.C., Colombia
Oncomedica
Montería, Departamento de Córdoba, Colombia
Hospital Pablo Tobon Uribe
Robledo, Medellín, Colombia
Centro Médico Nacional Siglo XXI
Mexico City, Not Aplicable, Mexico
INCan
Mexico City, Not Aplicable, Mexico
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Carlos Barrios
Latin American Cooperative Oncology Group
- PRINCIPAL INVESTIGATOR
Gustavo Werutsky
Latin American Cooperative Oncology Group
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Target Duration
- 3 Years
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 11, 2018
First Posted
January 13, 2020
Study Start
July 25, 2018
Primary Completion
October 4, 2021
Study Completion
August 4, 2023
Last Updated
February 20, 2024
Record last verified: 2024-02